Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.

Wagner, Henrik; Angiolillo, Dominick J; Ten Berg, Jurrien M; Bergmeijer, Thomas O; Jakubowski, Joseph A; Small, David S; Moser, Brian A; Zhou, Chunmei; Brown, Patricia; James, Stefan; Winters, Kenneth J; Erlinge, David

Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.

Mark

Wagner, Henrik ^LU ; Angiolillo, Dominick J ; Ten Berg, Jurrien M ; Bergmeijer, Thomas O ; Jakubowski, Joseph A ; Small, David S ; Moser, Brian A ; Zhou, Chunmei ; Brown, Patricia and James, Stefan , et al. (2014) In Journal of Thrombosis and Thrombolysis 38(2). p.127-136

Abstract: Body weight is a predictor of clopidogrel response. However, no prospective studies have compared pharmacodynamic (PD) and pharmacokinetic (PK) data based on body weight. We compared PD and PK effects of clopidogrel 75 mg in low body weight (LBW, <60 kg) and higher body weight (HBW, ≥60 kg) patients with stable coronary artery disease. LBW (n = 34, 56.4 ± 3.7 kg) and HBW (n = 38, 84.7 ± 14.9 kg) aspirin-treated patients received clopidogrel 75 mg for 10-14 days. The area under the concentration-time curve of active metabolite (Clop-AM) calculated through the last quantifiable concentration up to 4 h postdose, AUC(0-tlast), was calculated by noncompartmental methods. Light transmission aggregometry (LTA) (maximum platelet aggregation and... (More); Body weight is a predictor of clopidogrel response. However, no prospective studies have compared pharmacodynamic (PD) and pharmacokinetic (PK) data based on body weight. We compared PD and PK effects of clopidogrel 75 mg in low body weight (LBW, <60 kg) and higher body weight (HBW, ≥60 kg) patients with stable coronary artery disease. LBW (n = 34, 56.4 ± 3.7 kg) and HBW (n = 38, 84.7 ± 14.9 kg) aspirin-treated patients received clopidogrel 75 mg for 10-14 days. The area under the concentration-time curve of active metabolite (Clop-AM) calculated through the last quantifiable concentration up to 4 h postdose, AUC(0-tlast), was calculated by noncompartmental methods. Light transmission aggregometry (LTA) (maximum platelet aggregation and inhibition of platelet aggregation to 20 μM adenosine diphosphate (ADP), and residual platelet aggregation to 5 μM ADP), VerifyNow(®) P2Y12 reaction units (PRU), and vasodilator-associated stimulated phosphoprotein phosphorylation platelet reactivity index (VASP-PRI) were performed. Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL. HBW patients had higher platelet reactivity as measured by LTA (all p ≤ 0.01), PRU (207 ± 68 vs. 152 ± 57, p < 0.001), and VASP-PRI (56 ± 18 vs. 39 ± 17, p < 0.001). More HBW patients exhibited high on-treatment platelet reactivity (HPR) using PRU (35 vs. 9 %) and VASP-PRI (65 vs. 27 %). Body weight correlated with PRU and VASP-PRI (both p < 0.001), and inversely with log transformed AUC(0-tlast) (p < 0.001). In conclusion, HBW patients had lower levels of Clop-AM, and higher platelet reactivity and rates of HPR than LBW subjects, contributing to their suboptimal response to clopidogrel. (Less)

Please use this url to cite or link to this publication: https://lup.lub.lu.se/record/4065709

author

Wagner, Henrik ^LU ; Angiolillo, Dominick J ; Ten Berg, Jurrien M ; Bergmeijer, Thomas O ; Jakubowski, Joseph A ; Small, David S ; Moser, Brian A ; Zhou, Chunmei ; Brown, Patricia and James, Stefan , et al. (More)

Wagner, Henrik ^LU ; Angiolillo, Dominick J ; Ten Berg, Jurrien M ; Bergmeijer, Thomas O ; Jakubowski, Joseph A ; Small, David S ; Moser, Brian A ; Zhou, Chunmei ; Brown, Patricia ; James, Stefan ; Winters, Kenneth J and Erlinge, David ^LU

(Less)

organization

Cardiology

publishing date

2014

type

Contribution to journal

publication status

published

subject

Cardiac and Cardiovascular Systems

in

Journal of Thrombosis and Thrombolysis

volume

38

issue

2

pages

127 - 136

publisher

Springer

external identifiers

pmid:24043374
wos:000338706400001
scopus:84904726025
pmid:24043374

ISSN

1573-742X

DOI

10.1007/s11239-013-0987-8

project

Helsingborg Resuscitation and Cardiovascular Research Group

language

English

LU publication?

yes

id

e97dfbc7-e9ee-4f88-b6b6-b1bd2469f1b4 (old id 4065709)

alternative location

http://www.ncbi.nlm.nih.gov/pubmed/24043374?dopt=Abstract

date added to LUP

2016-04-01 11:08:48

date last changed

2022-03-05 02:00:34

@article{e97dfbc7-e9ee-4f88-b6b6-b1bd2469f1b4,
  abstract     = {{Body weight is a predictor of clopidogrel response. However, no prospective studies have compared pharmacodynamic (PD) and pharmacokinetic (PK) data based on body weight. We compared PD and PK effects of clopidogrel 75 mg in low body weight (LBW, &lt;60 kg) and higher body weight (HBW, ≥60 kg) patients with stable coronary artery disease. LBW (n = 34, 56.4 ± 3.7 kg) and HBW (n = 38, 84.7 ± 14.9 kg) aspirin-treated patients received clopidogrel 75 mg for 10-14 days. The area under the concentration-time curve of active metabolite (Clop-AM) calculated through the last quantifiable concentration up to 4 h postdose, AUC(0-tlast), was calculated by noncompartmental methods. Light transmission aggregometry (LTA) (maximum platelet aggregation and inhibition of platelet aggregation to 20 μM adenosine diphosphate (ADP), and residual platelet aggregation to 5 μM ADP), VerifyNow(®) P2Y12 reaction units (PRU), and vasodilator-associated stimulated phosphoprotein phosphorylation platelet reactivity index (VASP-PRI) were performed. Mean AUC(0-tlast) was lower in HBW than LBW patients: 12.8 versus 17.9 ng h/mL. HBW patients had higher platelet reactivity as measured by LTA (all p ≤ 0.01), PRU (207 ± 68 vs. 152 ± 57, p &lt; 0.001), and VASP-PRI (56 ± 18 vs. 39 ± 17, p &lt; 0.001). More HBW patients exhibited high on-treatment platelet reactivity (HPR) using PRU (35 vs. 9 %) and VASP-PRI (65 vs. 27 %). Body weight correlated with PRU and VASP-PRI (both p &lt; 0.001), and inversely with log transformed AUC(0-tlast) (p &lt; 0.001). In conclusion, HBW patients had lower levels of Clop-AM, and higher platelet reactivity and rates of HPR than LBW subjects, contributing to their suboptimal response to clopidogrel.}},
  author       = {{Wagner, Henrik and Angiolillo, Dominick J and Ten Berg, Jurrien M and Bergmeijer, Thomas O and Jakubowski, Joseph A and Small, David S and Moser, Brian A and Zhou, Chunmei and Brown, Patricia and James, Stefan and Winters, Kenneth J and Erlinge, David}},
  issn         = {{1573-742X}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{127--136}},
  publisher    = {{Springer}},
  series       = {{Journal of Thrombosis and Thrombolysis}},
  title        = {{Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.}},
  url          = {{http://dx.doi.org/10.1007/s11239-013-0987-8}},
  doi          = {{10.1007/s11239-013-0987-8}},
  volume       = {{38}},
  year         = {{2014}},
}

Lund University Publications

LUND UNIVERSITY LIBRARIES

Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.